Publication List and Links

Allan DS, Holbein BE. Iron Chelator DIBI Suppresses Formation of Ciprofloxacin-Induced Antibiotic Resistance in Staphylococcus aureus. Antibiotics (Basel). 2022 Nov 17;11(11):1642. doi: 10.3390/antibiotics11111642. PMID: 36421286; PMCID: PMC9687013.

Allan DS, Parquet MDC, Savage KA, Holbein BE. Iron Sequestrant DIBI, a Potential Alternative for Nares Decolonization of Methicillin-Resistant Staphylococcus aureus, Is Anti-infective and Inhibitory for Mupirocin-Resistant Isolates. Antimicrob Agents Chemother. 2020;64(3):e02353-19. Published 2020 Feb 21. DOI: 10.1128/AAC.02353-19

Ang MTC, Gumbau-Brisa R, Allan DS, McDonald R, Ferguson MJ, Holbein BE, Bierenstiel M. DIBI, a 3-hydroxypyridin-4-one chelator iron-binding polymer with enhanced antimicrobial activity. Medchemcomm. 2018 Jun 18;9(7):1206-1212. DOI: 10.1039/c8md00192h. PMID: 30109009; PMCID: PMC6071711.

Arora N, Caldwell A, Wafa K, Szczesniak A, Caldwell M, Al-Banna N, Sharawy N, Islam S, Zhou J, Holbein BE, Kelly MEM, Lehmann C. DIBI, a polymeric hydroxypyridinone iron chelator, reduces ocular inflammation in local and systemic endotoxin-induced uveitis. Clin Hemorheol Microcirc. 2018;69(1-2):153-164. DOI: 10.3233/CH-189109. PMID: 29630535.

Chen J, Zhou J, Kelly M, Holbein BE, Lehmann C. Iron chelation for the treatment of uveitis. Med Hypotheses. 2017 Jun;103:1-4. doi: 10.1016/j.mehy.2017.03.029. Epub 2017 Mar 30. PMID: 28571790. DOI: 1016/j.mehy.2017.03.029

Dickson K, Liu S, Zhou J, Langille M, Holbein BE, Lehmann C. Selective sensitivity of the gut microbiome to iron chelators in polybacterial abdominal sepsis. Med Hypotheses. 2018 Nov;120:68-71. DOI: 10.1016/j.mehy.2018.08.018. Epub 2018 Aug 24. PMID: 30220344.

Fokam D, Aali M, Dickson K, Scott C, Holbein B, Zhou J, Lehmann C. The novel iron chelator, DIBI, attenuates inflammation and improves outcome in colon ascendens stent peritonitis-induced experimental sepsis. Clin Hemorheol Microcirc. 2020;76(2):241-261. DOI: 10.3233/CH-209207. PMID: 32925011.

Fokam D, Dickson K, Kamali K, Holbein B, Colp P, Stueck A, Zhou J, Lehmann C. Iron Chelation in Murine Models of Systemic Inflammation Induced by Gram-Positive and Gram-Negative Toxins. Antibiotics (Basel). 2020a May 26;9(6):283. DOI: 10.3390/antibiotics9060283. PMID: 32466384; PMCID: PMC7345558.

Ghassemi-Rad, J, Fernando, W, Holbein, BE, Hoskin, DW. Iron withdrawal with DIBI, a novel 3-hydroxypyridin-4-one chelator iron-binding polymer, attenuates macrophage inflammatory responses. Adv Pharm Bull. 2023;13(2): 368-377. doi:10.34172/apb.2023.040

Greenshields AL, Power Coombs MR, Fernando W, Holbein BE, Hoskin DW. DIBI, a novel 3-hydroxypyridin-4-one chelator iron-binding polymer, inhibits breast cancer cell growth and functions as a chemosensitizer by promoting S-phase DNA damage. BioMetals. 2019 Dec;32(6):909-921. doi: 10.1007/s10534-019-00222-3. Epub 2019 Oct 17. PMID: 31624972. DOI: 1007/s10534-019-00222-3

Gumbau-Brisa, R.; Ang, M.T.C.; Holbein, B.E.; Bierenstiel, M. 2020. Enhanced Fe3+ binding through cooperativity of 3-hydroxypyridin- 4-one groups within a linear co-polymer: Wrapping effect leading to superior antimicrobial activity. BioMetals 33, 339–351. https://doi.org/10.1007/s10534-020-00253-1

Hagn G, Westhofen R, Burkovskiy I, Holbein B, Zhou J, Lehmann C. Iron Chelation as Novel Treatment for Interstitial Cystitis. Pharmacology. 2019;103(3-4):159-162.DOI: 10.1159/000496089. Epub 2019 Jan 29. PMID: 30695781.

Hagn G, Westhofen R, Burkovskiy I, Holbein B, Zhou J, Lehmann C. Iron Chelation as Novel Treatment for Interstitial Cystitis. Pharmacology. 2019;103(3-4):159-162. doi: 10.1159/000496089. Epub 2019 Jan 29. PMID: 30695781.

Harris G, Holbein BE, Zhou H, Xu HH, Chen W. Potential Mechanisms of Mucin-Enhanced Acinetobacter baumannii Virulence in the Mouse Model of Intraperitoneal Infection. Infect Immun. 2019 Oct 18;87(11):e00591-19. doi: 10.1128/IAI.00591-19. PMID: 31405959; PMCID: PMC6803341.

Holbein BE, Ang MTC, Allan DS et al.Iron-withdrawing anti-infectives for new host-directed therapies based on iron dependence, the Achilles’ heel of antibiotic-resistant microbes. Environ Chem Lett. 2021. https://doi.org/10.1007/s10311-021-01242-7

Holbein BE, Mira de Orduña R. Effect of trace iron levels and iron withdrawal by chelation on the growth of Candida albicans and Candida vini. FEMS Microbiol Lett. 2010 Jun;307(1):19-24. DOI: 10.1111/j.1574-6968.2010.01956.x. Epub 2010 Mar 19. PMID: 20402789.

Holbein, BE, Lehmann, C. Dysregulated Iron Homeostasis as Common Disease Etiology and Promising Therapeutic Target. Antioxidants 2023, 12, 671. https://doi.org/10.3390/antiox12030671

Islam S, Jarosch S, Zhou J, Parquet Mdel C, Toguri JT, Colp P, Holbein BE, Lehmann C. Anti-inflammatory and anti-bacterial effects of iron chelation in experimental sepsis. J Surg Res. 2016 Jan;200(1):266-73. doi: 10.1016/j.jss.2015.07.001. Epub 2015 Jul 8. PMID: 26235905. DOI: 1016/j.jss.2015.07.001

Lehmann C, Aali M, Zhou J, Holbein B. Comparison of Treatment Effects of Different Iron Chelators in Experimental Models of Sepsis. Life (Basel). 2021 Jan 14;11(1):57. DOI: 10.3390/life11010057. PMID: 33466819; PMCID: PMC7830599.

Lehmann C, Alizadeh-Tabrizi N, Hall S, Faridi S, Euodia I, Holbein B, Zhou J, Chappe V. Anti-Inflammatory Effects of the Iron Chelator, DIBI, in Experimental Acute Lung Injury. Molecules. 2022 Jun 23;27(13):4036. doi: 10.3390/molecules27134036. PMID: 35807282; PMCID: PMC9268372.

Lehmann C, Islam S, Jarosch S, Zhou J, Hoskin D, Greenshields A, Al-Banna N, Sharawy N, Sczcesniak A, Kelly M, Wafa K, Cheliak W, Holbein B. The utility of iron chelators in the management of inflammatory disorders. Mediators Inflamm. 2015;2015:516740. DOI: 10.1155/2015/516740. Epub 2015 Mar 23. PMID: 25878400; PMCID: PMC4386698.

Nocera FP, Iovane G, De Martino L, Holbein BE. Antimicrobial Activity of the Iron-Chelator, DIBI, against Multidrug-Resistant Canine Methicillin-Susceptible Staphylococcus pseudintermedius: A Preliminary Study of Four Clinical Strains. Pathogens. 2022 Jun 7;11(6):656. doi: 10.3390/pathogens11060656. PMID: 35745511; PMCID: PMC9227175.

Parquet MDC, Savage KA, Allan DS, Ang MTC, Chen W, Logan SM, Holbein BE. Antibiotic-Resistant Acinetobacter baumanniiIs Susceptible to the Novel Iron-Sequestering Anti-infective DIBI In Vitro and in Experimental Pneumonia in Mice. Antimicrob Agents Chemother. 2019; 23;63(9):e00855-19. DOI: 10.1128/AAC.00855-19. PMID: 31209004; PMCID: PMC6709489.

Parquet MDC, Savage KA, Allan DS, Davidson RJ, Holbein BE. Novel Iron-Chelator DIBI Inhibits Staphylococcus aureusGrowth, Suppresses Experimental MRSA Infection in Mice and Enhances the Activities of Diverse Antibiotics in vitro. Front Microbiol. 2018; 14;9:1811. DOI: 10.3389/fmicb.2018.01811. PMID: 30154764; PMCID: PMC6103240.

Power Coombs MR, Grant T, Greenshields AL, Arsenault DJ, Holbein BE, Hoskin DW. Inhibitory effect of iron withdrawal by chelation on the growth of human and murine mammary carcinoma and fibrosarcoma cells. Exp Mol Pathol. 2015 Oct;99(2):262-70. DOI: 10.1016/j.yexmp.2015.07.008. Epub 2015 Jul 22. PMID: 26210486.

Savage KA, Parquet MC, Allan DS, Davidson RJ, Holbein BE, Lilly EA, Fidel PL Jr. Iron Restriction to Clinical Isolates of Candida albicans by the Novel Chelator DIBI Inhibits Growth and Increases Sensitivity to Azoles In Vitro and In Vivo in a Murine Model of Experimental Vaginitis. Antimicrob Agents Chemother. 2018 Jul 27;62(8):e02576-17. DOI: 10.1128/AAC.02576-17.

Scott CR, Holbein BE, Lehmann CD. Iron should be restricted in acute infection. Front Biosci (Landmark Ed). DOI: 10.2741/4827 2020 Jan 1;25:673-682. PMID: 31585910.

Thorburn T, Aali M, Kostek L, LeTourneau-Paci C, Colp P, Zhou J, Holbein B, Hoskin D, Lehmann C. Anti-inflammatory effects of a novel iron chelator, DIBI, in experimental sepsis. Clin Hemorheol Microcirc. 2017;67(3-4):241-250. doi: 10.3233/CH-179205. PMID: 28869457. DOI: 3233/CH-179205

Zhang, X, Zhou, J, Holbein, BE, Lehmann, C. Iron Chelation as a Potential Therapeutic Approach in Acute Lung Injury. Life 2023, 13, 1659. https://doi.org/10.3390/life13081659